Walk The Road
BritePear Peptide U CJC-1295 + Ipamorelin
Peptide U by BritePear — Educational Series

CJC-1295 + Ipamorelin: The Growth Hormone Stack

Why these two peptides are almost always discussed together — and what it means for body composition, sleep, and recovery

⚡ TL;DR — Pear It Down

CJC-1295 and Ipamorelin are two peptides often used together to stimulate the body's own growth hormone release in a natural, pulsatile pattern. CJC-1295 is a GHRH analog (mimics the signal that tells your pituitary to release GH). Ipamorelin is a selective GH secretagogue with a clean side effect profile. Together they work synergistically. Both are investigational and not FDA-approved for general use.

Not medical advice. This is educational information for transparency purposes only. Always work with a qualified healthcare provider before starting any peptide protocol.

This is one of the most discussed stacks in the peptide world, and once you understand the mechanism it makes complete sense why. These two compounds work on the same system — your growth hormone axis — but from different angles, creating an effect that's greater than either alone.

Your Growth Hormone System, Briefly

Your pituitary gland releases growth hormone (GH) in pulses throughout the day, with the largest pulse typically occurring during deep sleep. GH drives fat metabolism, muscle protein synthesis, tissue repair, and cellular regeneration. As we age, these GH pulses become less frequent and less robust — starting as early as the mid-twenties.[1]

Two signals regulate this release from the hypothalamus: Growth Hormone-Releasing Hormone (GHRH), which triggers release, and somatostatin, which suppresses it. The balance between these determines how much GH you produce.

CJC-1295: The GHRH Analog

CJC-1295 is a synthetic peptide that mimics GHRH — specifically, it binds to GHRH receptors in the pituitary and stimulates GH release. The modified version (with DAC — Drug Affinity Complex) has a much longer half-life than natural GHRH, meaning fewer injections are needed to sustain the signal.[2]

Clinical studies in healthy adults demonstrated that CJC-1295 produced dose-dependent increases in GH and IGF-1 (insulin-like growth factor 1, which mediates many of GH's anabolic effects) with a favorable safety profile.[3]

Ipamorelin: The Clean GH Secretagogue

Ipamorelin works differently — it's a selective GH secretagogue that mimics the hormone ghrelin, binding to ghrelin receptors in the pituitary to stimulate GH release. What makes it particularly well-regarded is selectivity: unlike older GH secretagogues, it does not significantly raise cortisol, prolactin, or ACTH — hormones you generally don't want chronically elevated.[4]

Studies have shown Ipamorelin produces a strong, clean GH pulse with minimal interference with other hormonal systems — making it one of the better-tolerated peptides in this class.[5]

Why Stack Them?

GHRH (mimicked by CJC-1295) and ghrelin pathway agonists (mimicked by Ipamorelin) work on different receptors and synergize in the pituitary. Clinical and preclinical research shows that combining a GHRH analog with a GH secretagogue produces greater GH release than either alone — roughly additive to synergistic in effect.[6]

"The appeal of this stack is that it works with your body's existing feedback system rather than bypassing it. You're stimulating your pituitary to release your own GH in natural pulses — not injecting synthetic HGH directly."

Potential Benefits Studied

Research on GH optimization in adults with age-related GH decline has shown potential improvements in lean body mass, reduction in visceral fat, improved sleep quality (particularly deep sleep), and enhanced recovery from physical exertion.[7] For someone on a GLP-1 journey managing significant weight loss, the muscle preservation and metabolic implications of GH optimization are genuinely relevant conversations to have with your physician.

The Muscle Preservation Angle

One of the most significant concerns on any aggressive weight loss protocol — GLP-1 or otherwise — is losing lean muscle alongside fat. GH plays a key role in protein synthesis and muscle preservation. This is part of why the CJC-1295/Ipamorelin conversation has grown among people on GLP-1 medications looking to protect their body composition.[8]

⚠ FDA Status CJC-1295 and Ipamorelin are not FDA-approved for general use. CJC-1295 was studied in Phase I/II clinical trials but has not completed the approval process. Ipamorelin has been in clinical development. Both are considered investigational compounds. The FDA has restricted their use in compounding in some contexts. Always work with a licensed physician for any GH peptide protocol and verify current compounding regulations in your state.

Typical Protocol Notes

Physician-supervised protocols typically involve subcutaneous injection, often before bed to align with the body's natural GH pulse cycle. Because GH release is suppressed when insulin and blood sugar are elevated, these peptides are generally not taken with meals. Cycle structures vary; physicians often recommend periodic breaks to maintain pituitary sensitivity.

Side effects reported in studies include transient water retention, mild tingling or numbness, and occasional headaches — generally mild and dose-related.[3]

Sources & Citations

  1. Giustina A & Veldhuis JD (1998). Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews, 19(6), 717–797.
  2. Jetté L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295. Journal of Medicinal Chemistry, 48(1), 279–285. https://doi.org/10.1021/jm0494507
  3. Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
  4. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
  5. Johansen PB, et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106–113.
  6. Bowers CY (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329.
  7. Rudman D, et al. (1990). Effects of human growth hormone in men over 60 years old. New England Journal of Medicine, 323(1), 1–6.
  8. Treuth MS, et al. (1994). Effects of GH on body composition in older men. Journal of Applied Physiology, 77(6), 2663–2671.